146 related articles for article (PubMed ID: 32151507)
1. Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma.
Lin G; Li C; Li PS; Fang WZ; Xu HP; Gong YH; Zhu ZF; Hu Y; Liang WH; Chu Q; Zhong WZ; Wu L; Wang HJ; Wang ZJ; Li ZM; Lin J; Guan YF; Xia XF; Yi X; Miao Q; Wu B; Jiang K; Zheng XB; Zhu WF; Zheng XL; Huang PS; Xiao WJ; Hu D; Zhang LF; Fan XR; Mok TSK; Huang C
Ann Oncol; 2020 Apr; 31(4):517-524. PubMed ID: 32151507
[TBL] [Abstract][Full Text] [Related]
2. [The efficacy and influence factors analysis of EGFR TKIs on patients with lung adenosquamous carcinoma].
Zhou SY; Hu XS; Li JL; Wang Y; Liu YT; Xing PY; Yang JL; Lin H; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):776-781. PubMed ID: 30392343
[No Abstract] [Full Text] [Related]
3. Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.
Song Z; Lin B; Shao L; Zhang Y
J Chin Med Assoc; 2013 Sep; 76(9):481-5. PubMed ID: 23769878
[TBL] [Abstract][Full Text] [Related]
4. [Precision medical treatment of non-adenocarcinoma NSCLC patients with EGFR mutation].
Wang ZH; Song XY
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):90-93. PubMed ID: 28219201
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of Detecting Somatic Gene Mutations in Surgically Resected Adenosquamous Cell Carcinoma of the Lung in Japanese Patients.
Morodomi Y; Okamoto T; Takenoyama M; Takada K; Katsura M; Suzuki Y; Fujishita T; Kitahara H; Shimamatsu S; Kohno M; Tagawa T; Okano S; Taguchi K; Ichinose Y; Maehara Y
Ann Surg Oncol; 2015 Aug; 22(8):2593-8. PubMed ID: 25373537
[TBL] [Abstract][Full Text] [Related]
6. Mutation Profile of Resected
Zhao ZR; Lin YB; Ng CSH; Zhang R; Wu X; Ou Q; Chen W; Zhou WJ; Lin YB; Su XD; Shao YW; Long H
Oncologist; 2019 Oct; 24(10):1368-1374. PubMed ID: 30872465
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas.
Jin Y; Shi X; Zhao J; He Q; Chen M; Yan J; Ou Q; Wu X; Shao YW; Yu X
Lung Cancer; 2018 Oct; 124():110-116. PubMed ID: 30268447
[TBL] [Abstract][Full Text] [Related]
9. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
10. [The clinical and pathological features, biomarker characteristics and prognosis analysis of lung adenosquamous carcinoma].
Zhou SY; Xue Q; Ying JM; Hu XS; Yang JL; Lin H; Shi YK
Zhonghua Zhong Liu Za Zhi; 2019 Jan; 41(1):50-55. PubMed ID: 30678417
[No Abstract] [Full Text] [Related]
11. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
[TBL] [Abstract][Full Text] [Related]
12. Three new disease-progression modes in NSCLC patients after EGFR-TKI treatment by next-generation sequencing analysis.
Wei Y; Shen K; Lv T; Wang X; Li C; Fan H; Lv Y; Liu H; Song Y
Lung Cancer; 2018 Nov; 125():43-50. PubMed ID: 30429037
[TBL] [Abstract][Full Text] [Related]
13. The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.
Iwanaga K; Sueoka-Aragane N; Nakamura T; Mori D; Kimura S
Intern Med; 2012; 51(19):2771-4. PubMed ID: 23037472
[TBL] [Abstract][Full Text] [Related]
14. Deciphering the clonal relationship between glandular and squamous components in adenosquamous carcinoma of the lung using whole exome sequencing.
Krause A; Roma L; Lorber T; Habicht J; Lardinois D; De Filippo MR; Prince SS; Piscuoglio S; Ng C; Bubendorf L
Lung Cancer; 2020 Dec; 150():132-138. PubMed ID: 33137577
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China.
Zhou J; Song XB; He H; Zhou Y; Lu XJ; Ying BW
Asian Pac J Cancer Prev; 2016; 17(3):965-71. PubMed ID: 27039821
[TBL] [Abstract][Full Text] [Related]
16. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC.
Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?
Vassella E; Langsch S; Dettmer MS; Schlup C; Neuenschwander M; Frattini M; Gugger M; Schäfer SC
Oncotarget; 2015 Sep; 6(27):23905-16. PubMed ID: 26068980
[TBL] [Abstract][Full Text] [Related]
18. Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs.
Tang Y; Che N; Yu Y; Gao Y; Shi H; Feng Q; Wei B; Ma L; Gao M; Ma J; Lin D
J Cancer Res Clin Oncol; 2020 Feb; 146(2):407-416. PubMed ID: 31696302
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma.
Li C; Zheng X; Li P; Wang H; Hu J; Wu L; Wang Z; Guo H; Wu F; Zhong W; Zhou C; Chu Q; Zhao J; Zheng X; Xiao W; Zhu W; Zhang L; Li Q; Jiang K; Miao Q; Wu B; Xu Y; Wu S; Wang H; Yang S; Li Y; Xia X; Yi X; Huang C; Zhu B; Lin G
Front Immunol; 2022; 13():944812. PubMed ID: 36032124
[TBL] [Abstract][Full Text] [Related]
20. Frequency, clinical features and differential response to therapy of concurrent
Liu J; Mu Z; Liu L; Li K; Jiang R; Chen P; Zhou Q; Jin M; Ma Y; Xie Y; Xiang J; Li B; Ma Y; Mao X; Zhang L; Zhang T; Wu D
Drug Des Devel Ther; 2019; 13():1809-1817. PubMed ID: 31213769
[No Abstract] [Full Text] [Related]
[Next] [New Search]
